Summary
The study has 2 parts. The first part is open to adults with different types of advanced
cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not
successful.
The second part is open to people with non-small cell lung cancer with a specific
mutation in the HER2 gene.
The purpose of the first study part is to find the highest dose of a medicine called
zongertinib the participants can tolerate. Once this dose is found, it will be used in
the second study part to test whether zongertinib can make tumours shrink.
In this study, zongertinib is given to people for the first time. Participants take
zongertinib as tablets once a day or twice a day.
The participants are in the study for as long as they benefit from and can tolerate
treatment.
Study doctors regularly check the participants' health and monitor the tumours. The
doctors also take note of any unwanted effects that could have been caused by
zongertinib.